How does image guided TMS stack up against the current method?
In this episode we're doing another journal club, this time reviewing the first randomized clinical trial comparing image-guided TMS to the traditional method using scalp targeting for depression. We walk through how TMS works, why targeting matters, what the study found at one month, and where the limitations are before this becomes standard of care.
In this episode we're doing another journal club, this time reviewing the first randomized clinical trial comparing image-guided TMS to the traditional method using scalp targeting for depression. We walk through how TMS works, why targeting matters, what the study found at one month, and where the limitations are before this becomes standard of care.
Find the paper here: https://pubmed.ncbi.nlm.nih.gov/42340706/
Watch on YouTube: @itspresro
Listen Anywhere You Podcast: Apple, Spotify, PodChaser, etc.
—
Produced by Dr Glaucomflecken & Human Content
Get in Touch: howtobepatientpod.com
Learn more about your ad choices. Visit megaphone.fm/adchoices
Margaret: [00:00:00] I think a question I have sometimes with like these higher tech studies is not should we be doing them or should we not, but is like the money that goes into psychiatry and mental health care. I think there's many ethical ways to spend it, but I do think it's a question of like, would this money be better spent creating more access to this or creating more access to community mental health, like therapists?
Preston: Welcome back to How to Patient, the podcast where we cover things from psychodynamic ruminations down to the voxels of the granular, neuroscience research, and most things in between, including I think Kung Fu Panda recently- ... and improv. People like
Margaret: that episode.
Preston: So the real challenge is actually to predict what we're gonna talk about next, and if you're not sure, we aren't sure either, because- We
Margaret: aren't either.
Preston: This is on a week-by-week basis, baby.
Margaret: Only one of us-
Preston: But I
Margaret: am- ... ever knows what's [00:01:00] going on.
Preston: Yeah. It's like, you know those cats with a shared brain cell? Except- Mm-hmm ... Margaret and I have one. We just trade off who's got it each week. And this week I have it. And we- Hm ... are going to be talking about a fun paper on TMS, transcranial magnetic stimulation.
Margaret: I'm excited for this. it is interventional psych, I will say I know when it's indicated, but, like, reading more deeply on it is not a strong suit of mine, and I can own that. and so I'm excited to learn, and I superficially kind of looked at this paper, like, last week, so not a whole lot coming in from me.
So I am learning. If you guys also haven't fully read the paper, we're, the same. The... and so Preston's gonna teach us today.
Preston: Yeah, Preston will do his best. So dear listener, go ahead and get in the, the passenger seat with Margaret, and I will, I'll drive us through, the beauty of information in front of us.
So, [00:02:00] we- we're trying to do a shorter episode today, so we're not gonna do an expansive icebreaker. However, I do kinda wanna just feel things out, so Margaret, I know you know when it's indicated, know when it's not. You know, y- like in poker, you know when to hold 'em, you know when to fold 'em- Mm-hmm
regarding interventions. My question to you is what is your relationship with TMS? Have you ever actually participated in using the magnet? Have you experienced it? have you read about it?
Margaret: I've not. I've read about it. I've... I feel like I've, like, asked a lot of my, like, interventional psych, like, attendings or whatever, like, "Okay, when is this used and when is that?"
I think for me, it became clear kind of a couple years into residency that at least how interventional psych is now, that I wasn't gonna be the one- prescribing it or doing it probably, especially given my, like population interest. And so I think after that I was like, "Okay, when do I use elective time?"
But that being said, I think it's interesting-- I feel like TMS has like a few possible [00:03:00] indications and that, like the research is growing and it's an interesting intervention that can be helpful for people, but also it feels sometimes like it is something that's just thrown on for treatment-resistant things- Mm-hmm
like OCD or depression. so I don't really have a-- I've never s- I've-- Maybe I've seen it one, done like once. I've recommended it like a few times, but other than that, pretty minimal.
Preston: Yeah. So, so you're saying that you have a, a more peripheral relationship with it, which I think it's good for the audience and, for me explaining it to start from ground zero.
So when you think about how a magnet works, you can-- When you run, current through a wire, if you remember that right-hand rule, every, every electrical current will induce a magnetic field. Magnetic fields in-induce electrical fields. So we just- I feel like
Margaret: my, my like Pilates students when I'm like, "And you guys remember physics right now, right?"
Like, this is biomechanics. [00:04:00] Yeah. I feel like what they feel towards me right now. I'm like, "Yeah, right-hand rule, whatever." But-
Preston: Yeah, can't
Margaret: wait ... continue. this is why you take the physics in pre-med.
Preston: Yeah. Yeah. It comes back to you- It does ... just like how when you're telling your Pilates patients to be a cantilever, I'm telling them to get ready for Faraday's law.
Right. So yeah, you-- if you take a, a wire and run it in a coil, you can actually focus that magnetic field. And then when that magnetic field hits a nerve, it can induce a current in a nerve and it can activate it. It's kind of like magic. you can take a magnetic pulse and shoot it over your motor cortex and you can make your arm jump and you can see it in real time.
it's involuntary. it, feels eerie. So what we've found is that there are certain regions of the brain that are correlated in a causal way with depression. And what I mean by that is You can take a depressed person and run them through a scanner and see what, what regions of the brain are [00:05:00] hyperactive and hypoactive, or you can take regions of the brain that were stimulated or hit with a lesion and see if those led to depression or led to remission of depression.
So one thing that we've identified or one place that we've identified is, this dorsolateral prefrontal cortex has a causal relationship with depression. And if, you wanna find it anatomically, just think dorsum, like the back of your hand, the dorsum of your hand, the... And then lateral for outside, and then prefrontal for right before the frontal bone, prefrontal cortex.
So top dorsum lateral prefrontal cortex. So like right around here has a region that could be implicated in the, causation of depression. There's actually a lot of other regions. They're just not accessible via magnet. You can't stimulate them with a magnet.
Margaret: Yeah.
Preston: And that's- Some- ... that's another important thing, a- another important concept that we'll get into with this paper, which is that magnetic fields, they [00:06:00] Disperse and they dilute in power or signal in an exponential fashion.
So you lose signal really fast the farther you are away from something. And even though the cortex or the, the skull is only like a few centimeters thick, that's enough to really, disperse a lot of the signal. But because of that, we can't stimulate deeper brain structures. So something like deep brain stimulation can't be done from the outside with a magnet.
You actually have to go in and implant a, a stimulator, which is why you see like neurosurgeons putting in deep brain stimulators for something like Parkinson's. We'd love to stimulate with magnets from the outside, we just can't reach it.
Margaret: Right. that makes a lot of sense.
Preston: So a real quick thing on the logistics of it.
It's a frequent schedule. You have to go in about five times a week, so people don't like that aspect of it. But on the other hand, you have to take, a medication. There's no real side effects, there's no sedation involved, and it is a, a chance to actually get some precision in psychiatry.
Margaret: Versus if you compare it to like [00:07:00] ECT or ketamine- Yeah
where like you have to have someone drive you there and wait and come back, which like for these treatments that are like multiple times a week if not daily is-
Preston: Mm-hmm ...
Margaret: hard. And if you think about like what we're treating as like depression, amotivation, difficulty getting out of your home, doing day-to-day life things like as we might imagine that as low as we can make that barrier is best, but that TMS maybe has a little bit less of a barrier for some parts of logistics than other interventional approaches.
Preston: Yeah, absolutely. There are people that don't have a support system to drive them to and from appointments. And for a lot of patients, they will, do TMS while also taking a medication at the same time.
Margaret: Mm-hmm.
Preston: So they don't-- one doesn't preclude the other. They're... Because you're stimulating something and, that can cause irritation, there's a theoretical risk of seizures.
So sometimes if someone has like uncontrolled seizures or epilepsy, that's gonna be a contraindication, but it's [00:08:00] mostly on a case by case basis. If you look at the literature, there's only been a couple cases of a seizure that was, precipitated by TMS, and they- Mm-hmm ... all of those seizures stopped the second they turned the magnet off.
Margaret: Yeah.
Preston: But if you're stimulating electrical activity of the brain and uncontrolled electri- electrical activity running across your cortex is what causes a seizure, you could see how the two are related.
Margaret: Yeah. What do you think about like... I guess, what's your experience been for people reporting like topical irritation with like...
or pain with it? 'Cause I... My, my sense and from most people I've heard is that it's like pretty minimal. But I have heard of some people having like pretty, like they have found it more painful than other people. but I don't
Preston: know what your experience is. So I have done, I've had about three or four motor thresholds done on myself, which is like calibrating the magnet.
I haven't had [00:09:00] a full treatment done, which would be like a 15-minute session. And what I can say is that when the magnet, like the impulse is coming through, it doesn't necessarily hurt on the surface as much, but what does hurt, or what I've noticed, is that it will hit something like your facial nerve and that will cause it to twitch.
Margaret: Yeah.
Preston: And so that constant like twitching of the, your facial muscles being activated by your facial nerve can contribute to getting like a headache after the session-
Margaret: Gotcha. Yeah ...
Preston: or some, some discomfort. I can also appreciate that having, you know, a continuous theta burst over the course of 20 minutes could leave some irritation directly on the site that I might n- not be able to experience from, my motor thresholds that I've done just kind of doing it didactically.
And if that's really the, the biggest adverse effect, it's, or the most common complaint that relative to the other, side effects for medications is pretty mild.
Margaret: Mm-hmm. Yeah.
Preston: The reason we started with all this is because we're [00:10:00] looking at a paper where they're trying to find a more precise way to target the regions of your brain that are associated with depression.
A- and the, what we do right now is we use, just like phrenology, we use, I'm serious. I
Margaret: know, you
Preston: are. we literally use landmarks on your skull to figure out where to go. So when you're trying to calibrate the magnet, you'd like take a tape measure and it's the ... Oh my gosh, why am I forgetting the- Calipers?
there's a, that, that indent in between your eyes where your nose- Oh ... comes, it's like your glabellum or something.
Margaret: Oh yeah, that's- Gosh ... that's a word that's in there somewhere.
Preston: Anatomical landmarks. Your nasion. So
Margaret: that was tip of the tongue.
Preston: Yeah. Tip of- I would write
Margaret: that ...
Preston: it was right on your nose.
So you measure- I don't think I've
Margaret: heard that word in my life.
Preston: From your nasion to your inion, which is that prominent bony bump on the external occipital protuberance in the [00:11:00] back. So you measure the total distance there, and then you find these, like kind of the midpoints next to your tragus, and you use that...
Or sorry, the tragus on the side here.
Margaret: Mm-hmm.
Preston: And so you use that to kind of triangulate your map, and then you guess as to where someone's motor cortex would be, and you kind of move around until you see their hand react. Oh. And you're like, "Oh, we're closer to their motor cortex." And then you turn up the gain on the magnet, and you turn down the gain, gain on the magnet until you get them to twitch their thumb, just their thumb.
You don't want their arm flapping around. You're like, "Okay, I got, you know, I hit this pulse 10 times and his thumb twitched six times, so you know, we're kind of in the ballpark there." And then they just kind of guess. I don't want to say guess, but they move a couple
Margaret: centimeters down- They intelligently...
They guess in the same way, like injecting Botox into like-
Preston: E- exactly ...
Margaret: a muscle spasm in like CP is. Yeah.
Preston: And they hold the magnet over there and say, "We're just gonna hit you there." Now-
Margaret: Yeah
Preston: I'm [00:12:00] not gonna say like, "I feel happy, every time it hits me because my mood response isn't the same as my motor cortex responding.
So, you know, the doctor's like, "Am I right on the spot?" The patient's like, "I don't know if you're right on the spot. We're just kind of hitting it in the ballpark." So that- that's using anatomical, mapping to find it. What they did in this paper is they attempted to do or attempted to compare, I guess they successfully compared, image-guided, use of TMS, which it's not necessarily a new thing.
it's-- they used the Stanford neuroimaging techniques, which I think have come out about five years, or more ago, but this is the first time they actually did a head-to-head randomized control trial
Margaret: with
Preston: the two.
Margaret: Literally
Preston: head... Yeah, head to head. It's interesting 'cause you can put a ton of effort into, like, using an fMRI to figure out where exactly I should, like, target the magnet, but their question- Mm-hmm
is, like, does that actually- [00:13:00]
Margaret: Yeah, does it- ...
Preston: make it better than what we're doing right now?
Margaret: Increase efficacy or... Yeah.
Preston: Yeah. Because even though we have a relatively focal impulse, I think the best way to think about targeting someone's brain with a magnet is like throwing a pebble into a lake. It's gonna ripple out.
And if you're trying-- Like, let's say you're trying to hit a buoy with a rock. Do you... Y- you don't necessarily have to land the rock on the buoy if you're throwing these rocks out into the lake. You just have to get it close enough that the splash is gonna affect it.
Margaret: Right.
Preston: So, so the question is, you know, is using, you know, your binoculars and your cartograph thing and measuring the, the wind speed before you, you get it precise, is that gonna be better at, you know, stimulating the buoy than if you just throw it and just kinda guess it?
Well, who knows? We're trying to figure that out right now.
Margaret: And we're-- It always comes back to the primary care question of does it change management? And let's find out. Does
Preston: it change management? Yeah.
Margaret: Does throwing more money at this actually make this a better solution? [00:14:00]
Preston: So let's talk about how they even tried to do this in the first place, 'cause th- this is, kinda confusing, but it's also really interesting.
So they took, 40 patients, and they ran them through a resting state fMRI. And what they used that for was to kinda get an idea of how every single part of their brain is active at rest, and things, change over the course of rest. So, so they... Your brain, your neurons kinda go through these oscillations.
And we can see that those, are correlated to certain circuits and, certain neural networks. So there are a lot of, there's a lot of work in the early 2000s about funct- like resting state functional MRI neuro- neural networks, And what this was helpful for though, is that once we established a baseline for these patients, we had a reference point for converging circuits that have causal relationships with depression.[00:15:00]
So they basically took Thousands of data points from patients that either had stimulation or had a lesion that led to depression or was somehow related to depression, and they superimposed all of them, and they made a heat map of the brain and said, "These regions have strong associations with depression, strong causal relationships with depression, and these regions don't."
Margaret: And if you replace the words causal with correlated, correlative, in that... 'Cause one, one of the things you just described is, like, more of a, like, I would think of as, like, correlation rather than causal. And I- you gave the example earlier of, like, when we look at, like, lesions, and then it results in a picture that looks like depression.
but I feel like one of the things with, like, imaging studies and correlation versus causation with them is that it's pretty hard to pick apart. And so I'm just... I'm wondering what you mean when you say causal. Like, how do we know that it's causal versus only being able to say that it's correlative?
Preston: So [00:16:00] we're operating on the assumption that it's causal because this, a change or stimulation or a loss of function in this region of the brain then led to either the worsening or the, relieving of depressive symptoms. So-
Margaret: From, like, it- from, like, s- stroke studies or, like- Yeah ... lesion studies? From,
Preston: like, a stroke.
Okay, got it. Exactly. Got
Margaret: it.
Preston: Yeah. So a, a sim- the simplest way to put it is we looked at all the places that people got strokes and developed depression-
Margaret: Yeah ...
Preston: and then we mapped it.
Margaret: So not as, not established from this study, but established- Mm-hmm ... from prior studies. From
Preston: elsewhere, yeah. And so, and everyone has access to this.
This is a, it's a kind of a converging depression circuit, and I'm gonna share my screen really quick and kind of show you what that looks like. If you can kind of see the red, white, and blue regions here. So this is, the three different, So
Margaret: you got your cherry
Preston: flavored brain ... anatomical axes of the brain.
Yeah.
Margaret: Your lemon icy flavor, and then you've got your... Sorry.
Preston: Yeah. You got your rocket pop, [00:17:00] right?
Margaret: Yeah, exactly.
Preston: So, so here are the regions in red. These are gonna be positively correlated or strongly correlated with changes in your depression scale. And then blue is gonna be less correlated. So if we go and try to find our magical region, so I'm kind of hovering the axis right here for those of you on video over that dorsolateral prefrontal cortex.
You'll notice that it has, it's red hot, it has a really strong correlation or really strong causal relationship with, changes in depressive symptoms. And the, the reason why I'm being so, strict about that language is that if you were to take someone with depressive symptoms and put them under an fMRI, you may not see the same heat map because activity in dep- while you're actively in depression is gonna be different than a, a causal relationship.
And what we're trying to do is introduce a stimulus that might make a change in someone's depression
Margaret: And so is the blue areas-- 'cause, like, there's some of this, for those of u- for those of you who are listening, there's some areas on the brain here that are, like, not in a color at [00:18:00] all, and you're saying blue is, like, less associated.
Like, is the blue having... Is it, like, anti-associated, or is it, like, what is the difference between blue and, like, yellow or, like, the areas on the brain here that aren't, don't have any color at all? So
Preston: I wouldn't say it's anti-associated. I would say it has a less strong association. So like the R, so the R value is like closer to zero rather than-
Margaret: Got it
Preston: a big negative correlation.
Margaret: Okay.
Preston: and then the, these kind of like grayer, not colored areas, most of these are really just the white matter tracks.
Margaret: Got it.
Preston: Okay. And then there's like other like-- And then these could just be regions that have, like, no data on them or less data. Got
Margaret: it. Okay. That makes sense.
Preston: So when we kind of take that template, we can have someone run them through fMRI and then look at their brain activity and then map what parts of their brain activity associated with the red hot areas-
Margaret: Mm-hmm ...
Preston: on there specific to you. So- On the--
Margaret: Yes. Yeah.
Preston: So [00:19:00] each person had small differences compared to, like, if you did a structural MRI and saw where their cortex should land, and it was within the range of about five to 10 millimeters was the difference, so smaller.
And what they did is they took the dorsolateral prefrontal cortex and they took what's called a voxel, which is like a 3D pixel, and they ran all those pixels through the correlation and said which, which voxel has the strongest correlation to that time series connectivity from that template we had?
And that became their target. So then they're like, "Okay, let's focus the magnet position on this," and then they actually ran through a bunch of different magnet positions hoping to have the strongest correlation between that specific voxel.
Margaret: Okay. And so like- So the- Do you mean the cor- so, like, the correlation, like, when they were I guess I'm confused in that, like, they were looking [00:20:00] for the strongest overlap.
Like, 'cause we're trying to find the area that may, in theory, be the most effective to target, right? And so are you saying the overlap with the regions of, like, the known parts of the brain like that... I guess I'm confused of what comparing them, like, what does that draw out instead of just aiming it at the zones that you think it might be at?
Is it like there's a particular location that may be slightly different person to person of where those particular areas are, and so it's like then it would be better to focus it there?
Preston: Yeah. Yeah, so even-- It's like even if you did a structural MRI of that region and, like, were able to focus the magnet directly at where you think someone's dorsal, dorsolateral prefrontal cortex would be, if you look at it under fMRI, the actual activity that associates with those circuits might be a little bit different.
Margaret: Got it. That makes sense. Okay.
Preston: And so they focused only on the signal of the voxels and how they lined up with the map. [00:21:00] So, so it's like, it's hard to think about... So this is why I spend a lot of time-- I, I had to, like, go watch, like, lectures on fMRI to, like, better understand this, and even then I think it's hard for me to explain it and fully understand it myself.
But essentially, every single one of these voxels or pixels in your brain has a signal at any given point in time, and each one of those signals you then take and you compare it and say, "How close is this to this circuit, this template circuit map of the, causal relationship with depression?" And then the next second you, sample again, the next second you sample again.
And so of all of those, there's one set of voxels that has the closest relationship to it. You know, that sometimes it was stronger signal, sometimes it was less signal, but it, correlates. And then, That gives you what's called a time series or that squiggle line that you see a lot of these, these neuroscientists, yapping about.
So [00:22:00] here you can see this is the, actual paper, and these are all the different samples in time that I'm kind of hovering over it. It's just a squiggle line. And then they just did a lot of machine, computation to say which of these squiggles correlates the best to be the, simplest way. And, in a lot of ways, this is a guess.
Margaret: And so it goes from this broader area to the-- I have this paper also pulled up. So it goes from... Oh, I see. So there's the search space and they're like, "Okay, here's like the smaller area where this lines up in terms of like what you just described." And then in theory, that smaller space would be theoretically more, possibly more effective in terms of targeting with the intervention, in terms of like with the TMS.
Preston: Mm-hmm. Yeah, and that, that's the whole point is possibly. This is the hypothesis of the authors that if we have these different fields and we have the depression network time series, so from [00:23:00] the, the panel that's been-- we use this template for, some of them have like a R value of .49, some have .72, some have .21.
Well, let's pick the one with the strongest correlation to it, and then we'll pick that one to target within the dorsolateral prefrontal cortex.
Margaret: Cool.
Preston: So they did that, and then they found some interesting things. So the first one was that there was absolutely- Which we'll
Margaret: get back to right after our break.
Preston: Oh, yeah. we're gonna go to a break really quick. Let's let everyone- We're learning how
Margaret: to do cliffhangers, you guys.
Preston: We'll go to a break really quick. Let you guys digest, some of this stuff. Come up with questions that you can grill us later in the Spotify
Margaret: comments. Run through your voxels. That's the incorrect term.
I know some of you are neuroscientists who listen to this, so I know that's wrong. Anyway, we'll be right back.
Preston: Margaret and I are very excited to tell you about a healthcare news podcast that just came out called Medlines.
Margaret: It's a quick weekly wrap-up of everything in our field, from [00:24:00] breakthrough discoveries and research, to politics, and of course, medical pop culture.
Preston: I think the best way to conceptualize this podcast is it's like NPR's Up First, but for medicine.
So they're short, to the point, with episodes no longer than 15 minutes.
Margaret: And it's written and created by an amazing team, some of whom you might recognize: Dr. Glaucomflecken and Lady Glaucomflecken, as well as many people here at the Human Content Podcast Network.
Preston: With thanks for their inaugural sponsor, the New England Journal of Medicine.
New episodes of Medlines are out wherever you get your podcasts, with new episodes out every Friday.
A couple interesting things when they were able to apply these differences in techniques, and I think this is the perfect time to share my screen again actually. Picture's worth a thousand words here, I would say. So they found that the connectivity-based targeting versus kind of guessing with the scalp-based targeting had a difference in effect, particularly the longer they [00:25:00] went on in treatment.
So they looked at changes in the, MADRS, depression scale, which, it's just the Montgomery-Åsberg Depression Rating Scale. And they noticed similar changes in the first five days, but then after a month things started to differentiate a little bit, and there was a overall better response in the connectivity-based group.
Margaret: Mm-hmm.
Preston: The other thing that they found was that there was no correlation between the skull-based anatomical marker group and the connectivity-based group. So they-- When you mapped it with just using anatomical market, markers, then when you mapped it using the fMRI, they never found the same target, like ever.
Margaret: Yeah, that makes sense.
Preston: But even within the connectivity-based targets, there were some differences. So remember how we mentioned that it was kind of a guess and we're correlating it? So, so the researchers were aware of that and they said, "Okay, we had them sit in the fMRI for 40 minutes. What if we take all the data from the first half of the fMRI [00:26:00] and we run this, run it again, and then we take all the data from the second half of the MRI and then go through that same squiggly line analysis?"
And they found a, difference of about 4.5 millimeters in the points that came out of those two things. So remember this is all, based on correlation, kind of like a guesstimate of activity. However, that, that four, four and a half millimeters was much different than the about 12 to 13 millimeter difference between using the kind of the skull-based markers and then the connectivity markers.
And I think that's significant. It's about a full centimeter difference- Yeah ... or a third of an inch.
Margaret: And importantly, it's clinically significant. Correct. At least it looks like this. So like if you go into the comparison that they have in terms of like you're saying as it goes further on pa- like even into one week and then one month, the [00:27:00] two diverge in terms of the reduction of the depression symptoms.
And it goes from, what? They go from their baseline reduction from, goes from in five days negative like 16.5 points, and then the scalp base targeting kind of stays there and slowly increases, whereas the connectivity base goes to by one month minus 24 points- Yeah ... on symptoms. Scalp
Preston: base kind of plateaus- Yeah
but there's continuously some improvement in the connectivity
Margaret: base. which clearly means this one has cured depression. It'll just go down until you're super happy. It will never plateau. No.
Preston: Right.
Margaret: But yeah, but significant, it seems significant symptom reduction if I'm reading this correctly, right?
Preston: Mm-hmm. and you could argue that symptom reduction is due to a difference of [00:28:00] about 1.3 centimeters- of where the magnet is, placed in the angle
Margaret: of it. We're gonna get
Preston: better targeting. And I was curious like how much of a difference this might make, and so I was kind of researching the changes in the power of the magnet.
And one way to conceptualize it is that the power of the magnet is it's one over R squared is the difference. and that's the radius of like the magnet to the, that point you're looking at. So if you triangulate it, and I, kind of... I, used Claude to help me calculate this a little bit 'cause I, wasn't ready to go back to physics class.
it's, it could be up to a 40% to 60% reduction in the magnetic field in that area. So The, the, the... if there was a true singular best point to hit with the magnet, it's likely that the using connectivity-based targeting might get you within four millimeters of it, and using [00:29:00] scalp-based targeting might get you within 1.3 centimeters of it.
Margaret: Mm-hmm. Mm-hmm.
Preston: So it's about, you know, one-third is accurate. So there are some people that maybe get a really strong benefit, with the scalp-based targeting, but it's more so just luck that they happen to be hitting that right, the correct spot of their brain. And there are other people where, you know, the, actual spot's like here, and they're hitting it with the magnet here, and the magnetic field's still stimulating that part of their brain, but it's just has a less of effect, just like how a ripple comes out in a lake when you're throwing a stone.
Margaret: Right.
Preston: and that may explain why you have this still this initial change in depressive symptoms, but then it kind of plateaus.
Margaret: Yeah. Yeah. I mean, I would be curious, and certainly this is probably like you can look at, you can in some ways generalize to other TMS studies in terms of like long-term, like clinical effect size and then duration of impact after treatment like slows or [00:30:00] ends.
and then I can't remember if it was for this podcast or for the journal club I'm in for fellowship. I can't remember which one it is, which one we recently had a discussion on this. But the... Like what is, in terms of like clinical impact, reduction of 15 to 20 points on MADRS. Are you familiar with like is that something from like going to from moderate depression to-
Preston: So it could take you from moderate to looks like in remission.
Margaret: Okay. Yeah, so-
Preston: So zero to six is normal, seven to 19 mild, 20 to 30 moderate, 31 to 39 severe, 40 to 60 is extremely severe. So we saw at most minus 25, so that could take someone from moderate to no- normal, or it could take someone from extremely severe down to mild or moderate.
Margaret: Yeah. I think one of the things that would be interesting as well, and they put this in the limitations for the paper, but is that like on these charts we're looking at, that [00:31:00] there's almost...
There is no comparison to placebo in this study. but there's certainly almost definitely a, a significant placebo impact. And so, yeah, it would just be curious, like on, on its face, this looks promising in terms of like... And then when they talk in the discussion of like number needed to treat, like in terms of how many people to s- like scan or use this approach, for it to be worthwhile and, it seems...
You were saying also like time to time, maybe it says in the paper like time to time. It's not like they have to do the imaging Every time they do it. It's like kind of you can do it once and then you know where to put like the treatment. but it would be curious to be like if the study is a little bit longer continuing on-- if this trend continues for it to be more effective and then sustained more effective, and then also like if we take out the placebo on both sides, 'cause that was the other thing they put in limitations is that they felt like p- some people were able to guess pretty well that they were in the measurement-based [00:32:00] group in terms of-
Preston: Yeah.
And that was interesting, specifically the people that got a lot better, the people whose depression improved the most had better accuracy at guessing that they were in the connectivity-based group. Which
Margaret: is interesting.
Preston: I did think it was helpful that they included the most of the other participants had about a 50% success rate in guessing whether or not they were in the connectivity or scalp-based group, and the psychiatrist performing the actual, treatments also only was about 50% correct, so the same as flipping a coin, which is what you would expect.
So yeah, it's interesting. I think I agree that we need more longevity. I think the purpose of this paper at its core was, does using some kind of imaging guided based on functional con-connectivity, could we even detect a difference if we... Is it worth pursuing this path? Right now, fMRI is not very accessible, and it's pretty [00:33:00] expensive.
But as technology continues to progress, I imagine these technologies will, only become more convenient for us to use in the like interventional settings At least that's m- the optimistic part of myself. I'm thinking about how much of a luxury and a rich person thing it would be to have a cellphone, like one of those old brick cellphones in the '80s, and now everyone has an iPhone in their hand that's more powerful than what we used to, land on the moon.
And I think this is gonna be a similar thing, my hope in the next couple decades with, like, medical imaging. You know, at this point it's like you have to be at a specialized research center to get someone access to some sort of resting state fMRI they can use to calibrate the most likely treatment point of their brain with a magnet.
But that might be made a lot more convenient in, years to come, so, so it's worth seeing if it's gonna make a difference for someone medically.
Margaret: Yeah. On the m- the, the ethics of the kind of time and money of it as well are interesting in [00:34:00] terms of, like, can we make it-- Like, can it be done in a way that makes sense from a system perspective?
That it's like, oh, well, we use these for machines for research and for this way of targeting treatment, so it's, like, not another kind of, like, extra cost to a hospital system outside of, like, the research maybe, versus, like, what is the... I think in medicine there's-- Because the way that RVUs and insurance works at present is, like, procedural things are paid better than preventative care or more, like, quote-unquote, "emotional," like, care things.
Because if you can get a machine to do it and you can take human labor out of it, then eventually it pays for itself. But also, like, I, think a question I have sometimes with, like, these higher tech studies is not should we be doing them or should we not, but is, like, how does the money that goes into psychiatry and mental health care...
Like, I think there's many ethical ways to spend it, but I do think it's a question of, like, would this money be better spent... [00:35:00] I don't know the answer to this question. Would this money be better spent creating more access to this or creating more access to community mental health, like therapists? And, that's, like, a very oversimplified thing, but I think when we're talking about all of these, including when I'm talking about, like, psychoanalytic therapy, which is super rarefied in terms of all the things you have to do it, is, like, the question of time, money, and attention as resources in terms of how do we make mental health care better attached to all these conversations we have is interesting, and I think this is one, one part of that conversation.
Does that make sense? Mm-hmm.
Preston: Yeah. And it's undoubtedly expensive to distribute a lot of fu- or channel a lot of funding towards fMRIs.
Margaret: Which I don't think makes it not the right choice. I'm more just meaning- Yeah ... I think this, this, th- these big questions of, like, what is the best way for our communities and for whatever to distribute the resources is just like a-- I don't think it-- It's not something I was taught explicitly to think about in training [00:36:00]
Preston: Mm-hmm.
I think that this, like pushing this forward or like showing that it works is how we slowly get more funding towards access. Like, this is the foot in the door because if you can convince someone that like even, at the very beginning when they were doing those early TMS studies and, you know, we could have been having the same conversation in the '90s, "Hey, this guy says that if he uses a magnet on someone's brain, it can improve their depression.
They did a whole placebo trial on it." Well, you know, instead of spending all this money on these magnets, could be better spent giving people access to psychiatrists. Well, now because, like, that work was done in the studies, there is a little bit more access to it. But to be honest, not really. it's pretty hard.
It's still pretty hard to get into TMS.
Margaret: It-- And it would be hard to like, to play devil's advocate to if that money had been invested then. I mean, this is a problem with like primary care and why like no one... Like, [00:37:00] you would then have to trace if that money had gone somewhere else, like what are the downstream impacts of if there had been more access to psychiatric care in the '90s from like a systemic mental health and systems perspective.
Mm-hmm. But-
Preston: yeah. Would that have made, the difference we hoped it
Margaret: would have? But it's har- it's not sexy to try to sell that. Like, it's like- Mm-hmm ... "Hey, you know this thing that we're probably never gonna totally fix? This may make it 5% better for the next three years," versus like, "We have a new treatment."
So I think I, you know, we want funding for all of this, but it's just, it's interesting to think about.
Preston: Mm-hmm. Yeah. Where's money? That, was one thing I was gonna say is the, the other part of it is I almost wish we didn't have to, squabble between the like where the funding goes for mental health resources.
It's like, it makes me think of, you know, one neighbor scolding another neighbor for like leaving their car running in the parking lot while they get groceries. Meanwhile, there's like a, an oil tanker crossing the ocean right now that's gonna use more carbon [00:38:00] than you will in your entire lifetime. And it's like, you know, like ar- like arguing over pennies when like the real waste is like elsewhere.
And so it's like, I think we'll just, you know, everyone's on the same side. any amount of funding that goes towards mental health Is good funding.
Margaret: Yeah. I mean, I think that's true, and I think, like, the reality is of, like, even how you think of from a small as how do you sort your time as an attending or, like, how do you choose what you get let be and reimbursed, how do you choose h- like, what kind of group you practice in, all the way up to, like, bigger decisions made at, like, the law level.
I agree with you that it's like, okay, well maybe the... You know, there are bigger things that deserve more time in terms of, like, where is money going or not going, and the way that things are actually logistically practiced, at least from what I see for the time being and from what I see in my-- on my dad's career, is, like, these kinds of conversations at the local level [00:39:00] also are And I don't know, are what makes the actual care decisions.
That being said, I also like that there's been fMRI stuff now on, like, why does therapy work and what is the impact of long-term therapy on the brain? So ultimately, luckily, it's all happening in the same place. We need all of it 'cause we don't know a lot of shit still.
Preston: Yeah, it's... I mean, science is inevitably political, inevitably economic.
A- and also sometimes I like to just turn those parts of my brain off when I get to read about other parts of people's brains lighting up.
Margaret: Very fair.
Preston: well, thanks for going through this rather dense paper with me. I, It took me a while to, like, really conceptualize, and I don't think we did, an amazing job of describing, like, how they actually were trying to, piece out the functional connectivity and how it relates to the map.
But it's interesting that similar to having, you know, [00:40:00] ultrasound-guided IVs or IR-guided lumbar punctures, we now may- Mm-hmm ... have some sort of imaging-guided- Yeah ... stimulation technique for the treatment of depression. It's kind of the, the first of its kind in psychiatry, and to see that we now have a randomized control trial showing that it, is better than what we were using before or, has the potential to be.
obviously, the, the final conclusion of this is we need more trials, we need more patients in more trials, and we need to watch them for longer to see. All that being said, it's promising and it's exciting.
Margaret: And listeners, that's how you know this podcast is not a scam because every time we end it with, "And all that to say, keep up the good fight.
I'd like some more research." Much to consider.
Preston: And to give you context, like, that we, go through all this kind of robust research to say maybe. And, these are really [00:41:00] thoughtful, articulate scientists that care a lot about, ethical neuroscience.
Margaret: Mm-hmm.
Preston: To-- All this to say maybe.
and then you have other people coming out like the that run someone through a PET scan one time and say, like, "Oh, you actually have fireball
Margaret: ADHD."
Preston: Whoa, we're going full name drop. Allegedly. Allegedly. Allegedly, yeah
Margaret: Jason, can you beep out that name? When
Preston: we have certain not to be named, people out there running PET scans and then saying with complete, conviction that you have, like, a subtype of ADHD based on me just watching the activity of your brain.
It's, like, I cannot emphasize how much of a, I think an insult to people doing- Yeah ... like, the proper scientific method that is.
Margaret: Yeah. Which is part of the reason we have this podcast, is to talk about the papers, have some of the people who are actually doing the work on, and to talk about shit that's pissing us off.
I will say my version that [00:42:00] pisses me off that I've been seeing more has been less of actual people who are clinicians and more of, like, I feel like across, like, I don't know why I'm seeing it, but social media people being like, "As a nervous system regulator coach," or, like, "As a hormone coach," and I'm just like, what is all of it?
Like, are you seeing any of this that's popping up? That I'm like, why is this, like- No ... made up, like ... It's all, first of all, it's all marketed at women. It's like, although maybe there's, like, a testosterone coach. Like, "I'm a testosterone personal trainer." I will- But it's like, it's, like, made up terms that are basically then coming and being like, "And here's why you should listen to me about mental health."
And I'm all for videos people make, and this is my last tangent, I promise. But, like, when someone's like, "Hey, I'm not an expert. These are things that help me take care of myself. Take them as you will. I'm not gonna make random scientific claims," I think that's great and valid information for people. And, like, there's a reason, like, peer support works.
Mm-hmm. But when people are just, like, making up terms and are like, "I'm an executive [00:43:00] functioning cortisol neuroregulation, coach. Here's four things you didn't know about regulating your oxytocin," I'm, mad. But then I'm a bitch
Preston: It's stolen valor is what it is But then
Margaret: I'm a bitch,
Preston: yeah. You gotta-- you have to connect your authority with the claims that you're making.
Margaret: I'm gonna start marketing myself as...
Preston: Yeah, I, woke up this morning and I decided that I'm a, a cortisol coach. Oh, bye to your camera 'Cause who's gonna stop me? Okay, bye, I'm overheating. Well, we're g- we're gonna go dark as we do the outro.
Margaret: I love it.
Preston: th- thanks, thank you all for listening. I hope that we activated or stimulated some parts of your brain, listening to our discussion.
Those fossils are
Margaret: tingling.
Preston: Still wrong. we'd love to see those on an fMRI when we, buy one with all of our crazy ad money.
Margaret: Communal fMRI. How to Be- If
Preston: you wanna hear us, do our best to take down, more of these papers, let us [00:44:00] know. I like reading about them. I think it makes me a better doctor, and it's fun to, to bring them to y'all.
you can always find me yapping or doing whatever I am at my, TikTok account @presro or on YouTube @itspresro. That's also where we have a lot of our video episodes. You can also find episodes of the podcast on Spotify, Apple Music, or most other places you get your podcasts, as well as- Or on
Margaret: Patreon
Preston: yep, Patreon and howtobepatientpod.com. If you wanna find more of Margaret, she's @badarteveryday on TikTok, Instagram, Substack. She usually has some kind of challenge going on. I'm not tracking if you're doing something right now.
Margaret: It's the same one. I h- I... I'm just- Okay ... I be vibing. No challenges. Okay.
Preston: If you wanna be vibing, that's where Margaret will be.
shout out to everyone who's been leaving such supportive comments on Spotify and YouTube. There was a great response to our nuances in antidepressant prescribing. I thought you [00:45:00] guys really liked it. So Avery said on Spotify, "Psych pharmacist feeling well-fed this morning. I also avoid Wellbutrin if there is a concern for suicide history and dose-dependent seizure risk."
Thank you, Avery. and then Gabby said, "Just a suggestion for the foreign audience. Try to use medications' generic names instead of brand names. When you say sertraline, I get it, but then I get lost in the Prozacs and Lexapros being thrown around." That is also great feedback. We can do that. And we try our best to use generic names because we recognize that you're not all from, from the US and using our lingo.
Thanks again for listening. We're your hosts, Preston Roche and Margaret Duncan. Our executive producers are me, Preston Roche, Margaret Duncan, Will Flanary, Kristin Flanary, Aron Korney, Rob Goldman, and Shahnti Brooke. Our editor and engineer is Jason Portizo. Our music is by Omer Ben-Zvi. To learn more about our program disclaimer and ethics policy, submission [00:46:00] verification, licensing terms, and our HIPAA release terms, go to howtobepatientpod.com or reach out to us at howtobepatient@human-content.com with any questions or concerns.
How to Be Patient is a Human Content Production.
Thank you for watching. If you wanna see more of us or if you wanna see... This is Lilac. She's my cat. She's gonna be waving her hand at one of the floating boxes, which will lead to more episodes. Lilac, point to the other episodes. Lilac doesn't know what the internet is, but I swear they're there. They pr- they probably exist for real.
But in the meantime, I'm just gonna pet Lilac, and then I'm gonna go dance in the [00:47:00] background
RSS Feed